Stock GANX GAIN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Gain Therapeutics, Inc.

Equities

GANX

US36269B1052

Delayed Nasdaq
Other stock markets
 11:59:47 2024-05-02 am EDT 		5-day change 1st Jan Change
2.95 USD -0.67% Intraday chart for Gain Therapeutics, Inc. -3.91% -9.65%
Apr. 24 Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287 CI
Apr. 08 Gain Therapeutics Names Gene Mack as CFO MT

Evolution of the average Target Price on Gain Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3aea16159499b76f90f2f.9CJq5VoyIm_qPBJI80EEz3bOYjHV8PxjgnHYylL9KkY.smUjrh9kWwKBEXQR3jhuu0WHIwDtnLcC-wfsjWW8HxK2QCGdMFRtBbVeXw~96828c041f935d2a5e285dcb61125e17

Analyst Recommendations on Gain Therapeutics, Inc.

HC Wainwright Trims Price Target on Gain Therapeutics to $9 From $10, Keeps Buy Rating MT
Maxim Starts Gain Therapeutics at Buy With $10 Price Target MT
Chardan Raises Price Target on Gain Therapeutics to $6 From $5.75, Keeps Buy Rating MT
Chardan Raises PT on Gain Therapeutics to $5.75 From $4 on Plans to Advance Lead Drug Candidate to Clinical Trials, Reiterates Buy Rating MT
Chardan Ups Price Target on Gain Therapeutics to $5.75 From $4, as Lead Therapeutic Candidate Advances Into Clinic, Reiterates Buy Rating MT
Chardan Initiates Gain Therapeutics With Buy Rating, Price Target is $4 MT
Oppenheimer Lowers Gain Therapeutics' Price Target to $10 From $30, Maintains Outperform Rating MT
BTIG Lowers Price Target on Gain Therapeutics to $10 From $30, Maintains Buy Rating MT
B. Riley Downgrades Gain Therapeutics to Neutral from Buy, Says Filing Delay of Parkinson's Disease Lead Candidate Worsens Financing Overhang; Lowers PT to $5 from $11 MT
B. Riley Lowers Gain Therapeutics' Price Target to $11 from $16 to Reflect Increased Long-Term Cost of Capital Amid Current Macro Conditions; Keeps Buy Rating MT
B. Riley Lowers Gain Therapeutics' PT to $16 from $21 to Reflect Higher OpEx Spend Trajectory to Support Expanding Pipeline Activities, Keeps Buy Rating MT
HC Wainwright Initiates Gain Therapeutics at Buy With $12 Price Target MT
B. Riley Starts Gain Therapeutics at Buy with $21 PT, Encouraged by Drug Discovery Approach that Allows for Initial Focus on Lower-Risk Pipeline Programs MT
GAIN THERAPEUTICS : Oppenheimer Initiates Coverage on Gain Therapeutics With Outperform Rating, $30 Price Target MT
GAIN THERAPEUTICS : BTIG Research Initiates Coverage on Gain Therapeutics With Buy Rating, $30 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.97 USD
Average target price
8.8 USD
Spread / Average Target
+196.30%
High Price Target
10 USD
Spread / Highest target
+236.70%
Low Price Target
6 USD
Spread / Lowest Target
+102.02%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Gain Therapeutics, Inc.

HC Wainwright
Maxim
Chardan Research
Oppenheimer
BTIG
B. Riley

Ratings for Gain Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. GANX Stock
  4. Consensus Gain Therapeutics, Inc.